NIR-II light-driven <i>in situ</i> nanovaccine for cancer immunotherapy via lymph node migration-mediated accumulation.

ABSTRACT: Background: Tumor vaccines that combine tumor antigens with immune adjuvants offer a promising strategy for cancer immunotherapy. A particularly effective approach involves the in situ generation of tumor antigens within the tumor microenvironment and their subsequent delivery to the lymph nodes alongside immune adjuvants. However, Co-delivery of antigen and adjuvant on a single nano-platform remains facing some key problems, such as a single nanomedicine cannot simultaneously achieve antigen production, capture, and delivery to lymph nodes, as well as leakage of adjuvant due to destruction of nano-drug by exogenous stimuli and failure to capture antigen effectively. Methods: To address this, this study develops two synergistic nanodrugs: AuP and VNP_R848. Un

SUBMITTER: Huang Y 

PROVIDER: S-EPMC12316039 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature